Nanhua Biotech announced that the company's stock closed for four consecutive trading days from September 17 to September 22, 2026, with a cumulative increase of 46.43%. The closing price rose from 8.27 yuan to 12.11 yuan. Currently, the price-earnings ratio is about 104.33 times. The short-term increase in stock prices is large. There are characteristics of overheated market sentiment and irrational speculation, and the possibility of significant subsequent stock price fluctuations is not ruled out. The company's main business is biomedicine and energy saving and environmental protection. Cell therapy-related technologies and products are still in the R&D stage, and no innovative drugs have been marketed or entered into clinical trials; the major asset restructuring plan to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. was terminated on January 22, 2026, and there is currently no CRO business. There have been no major changes in the company's recent business conditions or internal and external business environment, and there are no important matters that should be disclosed but not disclosed. Investors are kindly requested to invest rationally and pay attention to risks.

Nanhua Biotech announced that the company's stock closed for four consecutive trading days from September 17 to September 22, 2026, with a cumulative increase of 46.43%. The closing price rose from 8.27 yuan to 12.11 yuan. Currently, the price-earnings ratio is about 104.33 times. The short-term increase in stock prices is large. There are characteristics of overheated market sentiment and irrational speculation, and the possibility of significant subsequent stock price fluctuations is not ruled out. The company's main business is biomedicine and energy saving and environmental protection. Cell therapy-related technologies and products are still in the R&D stage, and no innovative drugs have been marketed or entered into clinical trials; the major asset restructuring plan to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. was terminated on January 22, 2026, and there is currently no CRO business. There have been no major changes in the company's recent business conditions or internal and external business environment, and there are no important matters that should be disclosed but not disclosed. Investors are kindly requested to invest rationally and pay attention to risks.